Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C27H44N4O5 |
| Molecular Weight | 504.6621 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCCC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCCCCCC(N)=O
InChI
InChIKey=XEUVNVNAVKZSPT-JTJYXVOQSA-N
InChI=1S/C27H44N4O5/c1-4-6-8-12-24(34)30-22(18-20-13-15-21(32)16-14-20)26(35)31-25(19(3)5-2)27(36)29-17-10-7-9-11-23(28)33/h13-16,19,22,25,32H,4-12,17-18H2,1-3H3,(H2,28,33)(H,29,36)(H,30,34)(H,31,35)/t19-,22-,25-/m0/s1
| Molecular Formula | C27H44N4O5 |
| Molecular Weight | 504.6621 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 01:30:19 UTC 2023
by
admin
on
Sat Dec 16 01:30:19 UTC 2023
|
| Record UNII |
9WYX65A5C2
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
129010512
Created by
admin on Sat Dec 16 01:30:19 UTC 2023 , Edited by admin on Sat Dec 16 01:30:19 UTC 2023
|
PRIMARY | |||
|
1401708-83-5
Created by
admin on Sat Dec 16 01:30:19 UTC 2023 , Edited by admin on Sat Dec 16 01:30:19 UTC 2023
|
PRIMARY | |||
|
DIHEXA
Created by
admin on Sat Dec 16 01:30:19 UTC 2023 , Edited by admin on Sat Dec 16 01:30:19 UTC 2023
|
PRIMARY | Dihexa, also known as N-hexanoic-Tyr-Ile-(6) aminohexanoic amide, is an oligopeptide and angiotensin IV-derived drug that binds with high affinity to hepatocyte growth factor (HGF) and potentiates its activity at its receptor, c-Met. Dihexa dramatically improves cognitive function in animal models of Alzheimer's disease-like mental impairment. In an assay of neurotrophic activity, Dihexa was found to be seven orders of magnitude more potent than brain-derived neurotrophic factor. | ||
|
DIHEXA
Created by
admin on Sat Dec 16 01:30:19 UTC 2023 , Edited by admin on Sat Dec 16 01:30:19 UTC 2023
|
PRIMARY | The pharmacology of Dihexa in animals is well-documented: in vitro, the synaptogenesis of Dihexa begins at T+30:00, maximizes at +48:00:00. The overall half-life of the drug is currently charted at approximately a week: longer than just about any other neurogenic compound.Read more: http://www.nootropix.com/dihexa-story-and-science-of-a-neurogenic-wonder-drug/#ixzz454OKqZ00 | ||
|
DTXSID701032895
Created by
admin on Sat Dec 16 01:30:19 UTC 2023 , Edited by admin on Sat Dec 16 01:30:19 UTC 2023
|
PRIMARY | |||
|
9WYX65A5C2
Created by
admin on Sat Dec 16 01:30:19 UTC 2023 , Edited by admin on Sat Dec 16 01:30:19 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
TARGET -> ACTIVATOR |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PRODRUG -> METABOLITE ACTIVE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
